Overview

Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients

Status:
Terminated

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

The primary purpose is to investigate whether the addition of sodium valproate will be superior to treatment with quetiapine (Seroquel) given as monotherapy for an additional 14 days in non-responding patients after a 14 day initial treatment period with quetiapine. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Quetiapine Fumarate
Valproic Acid